Table 1 Baseline characteristics of patients on second line (2nd Line) ART
From: Outcome of patients on second line antiretroviral therapy under programmatic condition in India
Variable | Number (n = 170) | |
|---|---|---|
Age(years) | Mean ± SD | 36.78 ± 7.30 |
Median (IQR) | 35.0 (32.0-42.0) | |
Sex | Male n (%) | 141 (82.9) |
Female n (%) | 29 (17.1) | |
Duration of Immunological failure (months) | Mean ± SD | 17.30 ± 15.71 |
Median (IQR)a | 12 (6.0-23.0) | |
Weight(Kg) at the start of 2nd line ART | Mean ± SD | 48.34 ± 9.07 |
Median (IQR)a | 49.0 (41–55) | |
Clinical Stage at the start of 2nd line ART | I + II n (%) | 118 (69.4) |
III + IV n (%) | 52 (30.6) | |
CD4 count at the start of 2nd line ART (/μL) | Mean ± SD | 94.36 ± 72.98 |
Median (IQR)a | 78.50 (49.75-121.25) | |
Viralload baseline (copies/ml) | Mean ± SD | 490000.00 ± 1150000.00 |
Median (IQR)a | 1770000 (67375–3540000) | |
Last NRTI regimen | Stavudine n (%) | 81 (47.6) |
Zidovudine n (%) | 89 (52.4) | |
Total Duration of 2nd line ART (months) | Mean ± SD | 26.65 ± 16.76 |
Median (IQR)a | 22.50 (14–40.25) | |
Tuberculosis during 1st line ART | Yes n (%) | 89 (52.4) |
No n (%) | 81 (47.6) | |
Tuberculosis during 2nd line ART | Yes n (%) | 33 (19.4) |
No n (%) | 137 (80.6) | |
1st line ART Adherence | Adherence (<80-95 % ) n (%) | 46 (27.1) |
Adherence (>95 %) n (%) | 124 (72.9) | |
2nd line ART Adherence | Adherence (<80 %-95 %) n (%) | 38 (22.4) |
Adherence (>95 %) n (%) | 132 (77.6) | |